🇺🇸 FDA
Patent

US 9353124

Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

granted A61PA61P13/12A61P17/06

Quick answer

US patent 9353124 (Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P13/12, A61P17/06, A61P19/00, A61P19/02